<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00634998</url>
  </required_header>
  <id_info>
    <org_study_id>10046-001</org_study_id>
    <secondary_id>06H-2958-9918</secondary_id>
    <nct_id>NCT00634998</nct_id>
  </id_info>
  <brief_title>Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy</brief_title>
  <official_title>Vitamin C Supplementation as a Preventive Treatment of Diabetic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to determine whether vitamin C supplementation is
      beneficial in treating and/or preventing diabetic peripheral neuropathy in people with type 2
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Painful diabetic peripheral neuropathy (DPN), a condition characterized by pain affecting the
      feet, legs and hands that is often characterized as burning or a &quot;pins and needles&quot;
      sensation, is estimated to affect up to 66% of the U.S. diabetic population. This pilot study
      will examine the effect of a daily dose of ascorbic acid, a known aldose reductase inhibitor,
      versus placebo, and the effect that it can have on intracellular erythrocyte (red blood cell)
      sorbitol levels, aldose reductase activity and aldose reductase enzyme levels utilizing
      benchtop methods, and effects on clinical DPN-associated pain reporting and changes in
      quantitative sensory testing in the lower extremities via touch discrimination and vibratory
      sensory testing in patients with Type 2 Diabetes Mellitus (T2DM) over the course of 90 days
      of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in intracellular erythrocyte sorbitol levels</measure>
    <time_frame>Changes at 90 days compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in aldose reductase enzyme activity</measure>
    <time_frame>Activity at 90 days compared to baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in aldose reductase enzyme levels</measure>
    <time_frame>Levels at 90 days compared to baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Neuropathic Pain Scale (NPS) measurement and quantitative sensory testing in the lower extremities via touch discrimination with Semmes-Weinstein monofilaments and vibratory sensation testing</measure>
    <time_frame>Changes at 90 days compared to baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Diabetic Neuropathies</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1000mg Placebo capsules orally twice daily for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg Vitamin C capsules orally twice daily for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>1000mg Vitamin C capsules orally twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1000mg Placebo capsules orally twice daily for 90 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 2 diabetes mellitus

          -  diabetic peripheral neuropathy

          -  A1C of 6.0-10.0%

        Exclusion Criteria:

          -  Terminal diagnosis

          -  Dementia

          -  Anemia

          -  Significant renal dysfunction

          -  History of B-12 deficiency

          -  Peripheral vascular disease

          -  Current smoker

          -  History of kidney stones

          -  Current ascorbic acid use

          -  Presence or foot infection and/or ulcer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua J Neumiller, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington State University, College of Pharmacy, Department of Pharmacotherapy</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99210-1495</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2008</study_first_submitted>
  <study_first_submitted_qc>March 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin C</keyword>
  <keyword>Ascorbic Acid</keyword>
  <keyword>Diabetic Neuropathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

